The Biology of Type 2 Diabetes & Emerging Subtypes
At a Glance
Type 2 Diabetes is not a single disease, but a collection of five distinct biological subtypes. Identifying whether your diabetes is driven more by severe insulin resistance, beta-cell failure, or age can help your doctor personalize your treatment and actively prevent specific complications.
While Type 2 Diabetes (T2DM) is often treated as a “one-size-fits-all” condition, modern science shows it is actually a collection of different biological subtypes [1]. Understanding which “cluster” you belong to can help you and your doctor predict which complications you are most at risk for and choose the most effective treatments [2][3].
The Biology of Beta-Cell Failure
To understand T2DM, you must understand the beta-cells in your pancreas. In Type 1 Diabetes (T1DM), the body’s immune system mistakenly attacks and destroys these cells [4]. In Type 2 Diabetes, the story is different: your beta-cells are still there, but they are “burnt out” or struggling [5].
This struggle usually happens because your body has developed insulin resistance—your cells are ignoring the insulin your pancreas produces [6]. To keep up, your beta-cells work overtime until they experience internal cell exhaustion and mitochondrial dysfunction (a loss of cellular energy) [7][8]. Eventually, these cells may even “forget” they are beta-cells and stop producing insulin altogether [9].
The Five Clusters of Diabetes
Researchers have identified five distinct ways that diabetes can show up in the body. Knowing your cluster is a step toward precision medicine—treatment tailored specifically to your biology [10].
Note: The following subtypes represent emerging scientific research and may not yet be part of routine clinical testing today, but they show where the future of personalized care is heading [10].
| Cluster | Name | Key Characteristics | Main Risks [11][12] |
|---|---|---|---|
| SAID | Severe Autoimmune Diabetes | Similar to Type 1; occurs in adults; involves immune system antibodies. | Highest risk of eye disease (retinopathy). |
| SIDD | Severe Insulin-Deficient Diabetes | Low insulin production but no autoimmune antibodies; high HbA1c at diagnosis. | High risk of retinopathy and nerve damage (neuropathy). |
| SIRD | Severe Insulin-Resistant Diabetes | High body weight and severe insulin resistance; the body makes insulin, but cannot use it. | Highest risk of kidney disease and fatty liver disease. |
| MOD | Mild Obesity-Related Diabetes | Diagnosed at a younger age; associated with obesity but less severe than SIRD. | Generally lower risk of early complications. |
| MARD | Mild Age-Related Diabetes | Diagnosed at an older age; the most common type. | Usually progresses slowly with a lower risk of complications. |
Why This Matters for You
This isn’t just academic—it’s about your future health. For example, if you fall into the SIRD cluster, your doctor might prioritize protecting your kidneys earlier than they would for someone in the MARD cluster [1][13]. If you are in the SIDD group, you might need to monitor your vision more closely or start insulin therapy sooner to prevent “beta-cell burnout” [11][14].
Common questions in this guide
Why do beta-cells fail in Type 2 Diabetes?
What are the 5 clusters of diabetes?
What are the risks of Severe Insulin-Resistant Diabetes (SIRD)?
How does Severe Insulin-Deficient Diabetes (SIDD) affect the body?
Can knowing my diabetes subtype change my treatment plan?
Questions to Ask Your Doctor
Curated prompts to bring to your next appointment.
- 1.Based on my age, BMI, and HbA1c at diagnosis, which of the five diabetes clusters do I most likely fit into?
- 2.Have I been tested for GAD antibodies to see if I have an autoimmune component (SAID cluster)?
- 3.If I am in the SIRD (insulin-resistant) cluster, what extra monitoring should we do for my kidneys and liver?
- 4.Does my cluster profile suggest that certain medications, like SGLT2 inhibitors or early insulin, might be more effective for me?
Questions For You
Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.
References
References (14)
- 1
Risk of diabetes-associated diseases in subgroups of patients with recent-onset diabetes: a 5-year follow-up study.
Zaharia OP, Strassburger K, Strom A, et al.
The lancet. Diabetes & endocrinology 2019; (7(9)):684-694 doi:10.1016/S2213-8587(19)30187-1.
PMID: 31345776 - 2
Type 2 diabetes subgroups and potential medication strategies in relation to effects on insulin resistance and beta-cell function: A step toward personalised diabetes treatment?
Veelen A, Erazo-Tapia E, Oscarsson J, Schrauwen P
Molecular metabolism 2021; (46()):101158 doi:10.1016/j.molmet.2020.101158.
PMID: 33387681 - 3
Cluster Analysis in Diabetes Research: A Systematic Review Enhanced by a Cross-Sectional Study.
Taurbekova B, Sarsenov R, Yaqoob MM, et al.
Journal of clinical medicine 2025; (14(10)) doi:10.3390/jcm14103588.
PMID: 40429583 - 4
Fifty years of pancreatic islet pathology in human type 1 diabetes: insights gained and progress made.
Morgan NG, Richardson SJ
Diabetologia 2018; (61(12)):2499-2506 doi:10.1007/s00125-018-4731-y.
PMID: 30255378 - 5
Redox signaling in the pancreas in health and disease.
Sastre J, Pérez S, Sabater L, Rius-Pérez S
Physiological reviews 2025; (105(2)):593-650 doi:10.1152/physrev.00044.2023.
PMID: 39324871 - 6
Regulation of hepatic glucose metabolism in health and disease.
Petersen MC, Vatner DF, Shulman GI
Nature reviews. Endocrinology 2017; (13(10)):572-587 doi:10.1038/nrendo.2017.80.
PMID: 28731034 - 7
Therapeutic opportunities for pancreatic β-cell ER stress in diabetes mellitus.
Yong J, Johnson JD, Arvan P, et al.
Nature reviews. Endocrinology 2021; (17(8)):455-467 doi:10.1038/s41574-021-00510-4.
PMID: 34163039 - 8
Autophagy and its link to type II diabetes mellitus.
Yang JS, Lu CC, Kuo SC, et al.
BioMedicine 2017; (7(2)):8 doi:10.1051/bmdcn/2017070201.
PMID: 28612706 - 9
Evidence of β-Cell Dedifferentiation in Human Type 2 Diabetes.
Cinti F, Bouchi R, Kim-Muller JY, et al.
The Journal of clinical endocrinology and metabolism 2016; (101(3)):1044-54 doi:10.1210/jc.2015-2860.
PMID: 26713822 - 10
Replication and cross-validation of type 2 diabetes subtypes based on clinical variables: an IMI-RHAPSODY study.
Slieker RC, Donnelly LA, Fitipaldi H, et al.
Diabetologia 2021; (64(9)):1982-1989 doi:10.1007/s00125-021-05490-8.
PMID: 34110439 - 11
Comorbidities and mortality in subgroups of adults with diabetes with up to 14 years follow-up: a prospective cohort study in Sweden.
Asplund O, Thangam M, Prasad RB, et al.
The lancet. Diabetes & endocrinology 2026; (14(1)):29-40 doi:10.1016/S2213-8587(25)00283-9.
PMID: 41248671 - 12
Factors Associated with Risk of Diabetic Complications in Novel Cluster-Based Diabetes Subgroups: A Japanese Retrospective Cohort Study.
Tanabe H, Saito H, Kudo A, et al.
Journal of clinical medicine 2020; (9(7)) doi:10.3390/jcm9072083.
PMID: 32630741 - 13
Subtypes of newly diagnosed type 2 diabetes and risk of complications: analysis of electronic health records in the USA.
Li Z, Liu S, Ho JC, et al.
Diabetologia 2026; (69(6)):1545-1556 doi:10.1007/s00125-026-06687-5.
PMID: 41723302 - 14
Characterizing trajectories of diabetes-related health parameters before diabetes diagnosis in diabetes subtypes: analysis of a 20-year long prospective cohort study in Sweden.
Liedtke TP, Strathmann EA, Ahlqvist E, et al.
Cardiovascular diabetology 2025; (24(1)):244 doi:10.1186/s12933-025-02786-6.
PMID: 40490745
This page explains emerging research on Type 2 Diabetes subtypes for educational purposes only. It does not replace professional medical advice. Always consult your endocrinologist or primary care physician regarding your specific diabetes care and monitoring.
Get notified when new evidence is published on type 2 diabetes mellitus.
We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.